Literature DB >> 9174341

Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296.

M Kovalenko1, L Rönnstrand, C H Heldin, M Loubtchenkov, A Gazit, A Levitzki, F D Böhmer.   

Abstract

The mechanism of action of AG1296, a potent and specific inhibitor of the platelet-derived growth factor (PDGF) receptor tyrosine kinase [Kovalenko, M., Gazit, A., Böhmer, A., Rorsman, Ch., Rönnstrand, L., Heldin, C.-H., Waltenberger, J., Böhmer, F. D., & Levitzki, A. (1994) Cancer Res. 54, 6106-6114] was investigated. This quinoxalin-type tyrphostin neither interferes with PDGF-BB binding to the PDGF beta-receptor nor has any effect on receptor dimerization. Kinetic analysis of the inhibition was carried out using a synthetic peptide substrate (KY751) corresponding to the sequence around tyrosine 751 autophosphorylation site of the PDGF receptor. It revealed purely competitive inhibition vis-à-vis ATP, mixed competitive inhibition vis-a-vis the peptide substrate for the non-activated receptor, and mixed competitive inhibition vis-à-vis both substrates for the activated receptor. Thus, the type of inhibition apparently changes upon receptor activation, indicating conformational changes at the ATP-binding site. The high degree of selectivity for the tyrphostin AG1296 might result from the complex type of interaction with the active center of the receptor as revealed by the kinetic analysis. Dose-response curves for inhibition of the phosphorylation of individual autophosphorylation sites of the PDGF beta-receptor by AG1296 were different, phosphorylation of tyrosine 857 being the most susceptible to inhibition. Thus, phosphorylation of tyrosine 857 in the PDGF receptor kinase domain seems dispensable for partial kinase activation. The findings are discussed in relation to current models of receptor tyrosine kinase activation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174341     DOI: 10.1021/bi962553l

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  29 in total

1.  Protein kinase C-delta transactivates platelet-derived growth factor receptor-alpha in mechanical strain-induced collagenase 3 (matrix metalloproteinase-13) expression by osteoblast-like cells.

Authors:  Chuen-Mao Yang; Hsi-Lung Hsieh; Chung-Chen Yao; Li-Der Hsiao; Chin-Ping Tseng; Chou Bing Wu
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

2.  The platelet-derived-growth-factor receptor, not the epidermal-growth-factor receptor, is used by lysophosphatidic acid to activate p42/44 mitogen-activated protein kinase and to induce prostaglandin G/H synthase-2 in mesangial cells.

Authors:  M Goppelt-Struebe; S Fickel; C O Reiser
Journal:  Biochem J       Date:  2000-01-15       Impact factor: 3.857

3.  Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats.

Authors:  A B Rice; C R Moomaw; D L Morgan; J C Bonner
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

4.  CRSBP-1/LYVE-1 ligands disrupt lymphatic intercellular adhesion by inducing tyrosine phosphorylation and internalization of VE-cadherin.

Authors:  Wei-Hsien Hou; I-Hua Liu; Cheng C Tsai; Frank E Johnson; Shuan Shian Huang; Jung San Huang
Journal:  J Cell Sci       Date:  2011-04-15       Impact factor: 5.285

Review 5.  Biased signalling: from simple switches to allosteric microprocessors.

Authors:  Jeffrey S Smith; Robert J Lefkowitz; Sudarshan Rajagopal
Journal:  Nat Rev Drug Discov       Date:  2018-01-05       Impact factor: 84.694

6.  Epigallocathechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172).

Authors:  H Y Ahn; K R Hadizadeh; C Seul; Y P Yun; H Vetter; A Sachinidis
Journal:  Mol Biol Cell       Date:  1999-04       Impact factor: 4.138

7.  Lycopene binding compromised PDGF-AA/-AB signaling and migration in smooth muscle cells and fibroblasts: prediction of the possible lycopene binding site within PDGF.

Authors:  Ching-Pei Chen; Chi-Feng Hung; Shao-Chen Lee; Huey-Ming Lo; Pi-Hui Wu; Wen-Bin Wu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-17       Impact factor: 3.000

Review 8.  Blocking fibrotic signaling in fibroblasts from patients with carpal tunnel syndrome.

Authors:  Yoshiaki Yamanaka; Anne Gingery; Gosuke Oki; Tai-Hua Yang; Chunfeng Zhao; Peter C Amadio
Journal:  J Cell Physiol       Date:  2017-05-03       Impact factor: 6.384

9.  Mesenchymal chemotaxis requires selective inactivation of myosin II at the leading edge via a noncanonical PLCγ/PKCα pathway.

Authors:  Sreeja B Asokan; Heath E Johnson; Anisur Rahman; Samantha J King; Jeremy D Rotty; Irina P Lebedeva; Jason M Haugh; James E Bear
Journal:  Dev Cell       Date:  2014-12-04       Impact factor: 12.270

10.  Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.

Authors:  Shuji Ueda; Hirokazu Ikeda; Masao Mizuki; Jun Ishiko; Itaru Matsumura; Hirokazu Tanaka; Hirohiko Shibayama; Hiroyuki Sugahara; Emi Takai; Xian Zhang; Takashi Machii; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.